Pharmacologic Dose Testosterone to Treat Castration-Resistant Prostate Cancer: Mechanisms of Action and Drivers of Response

Abstract

Purpose: Single-arm studies have demonstrated preliminary signs of efficacy for intermittent pharmacologic dose testosterone (i.e. Bipolar Androgen Therapy; BAT) in treating advanced prostate cancer. In this project, we will conduct detailed molecular assessments on biospecimens (i.e. blood, metastatic tissue) from men receiving BAT to determine somatic and germline factors that predict for response/resistance. We will also evaluate additional PDT based regimens (e.g. combinatorial treatments) in preclinical models. Scope: This annual technical progress report details progress made during the first year of funding for this project (30 Sep 2016 1 Oct 2017).Major Findings: During Year 1 we have focused on biospecimen acquisition from men enrolled a Phase II study testing BAT vs. enzalutamide. Results from correlative and preclinical studies are not available at this time.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2017
Accession Number
AD1050397

Entities

People

  • Michael T Schweizer

Organizations

  • University of Washington

Tags

DTIC Thesaurus Topics

  • Acquisition
  • Biomedical Research
  • Blood
  • Breast Cancer
  • Carcinoma
  • Cell Physiological Processes
  • Cells
  • Chemistry
  • Colon Cancer
  • Genetic Structures
  • Genetics
  • Genomic Instability
  • Liver Diseases
  • Lymphocytes
  • Medical Personnel
  • Microsatellites
  • Neoplasms
  • Oncology
  • Prostate Cancer
  • Salivary Glands
  • Therapy
  • Tissues

Fields of Study

  • Medicine
  • Physics

Readers

  • Clinical Trial Research.
  • Oncology
  • Prostate Cancer Biology.